Latest Breaking News On - Clarity pharmaceuticals - Page 9 : comparemela.com

Registrational Phase III CLARIFY trial in prostate cancer commences

/PRNewswire/ Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products.

United statesNew south walesAlan taylorClarity pharmaceuticalsPrnewswire clarity pharmaceuticalsDrug administrationTechnology platformAmerican cancer instituteUrology cancer center xcancer omahaUrology cancer centerExecutive chairperson

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level
philippinetimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from philippinetimes.com Daily Mail and Mail on Sunday newspapers.

New south walesUnited statesAlan taylorLuke nordquistClarity pharmaceuticalsPrnewswire clarity pharmaceuticalsUrology cancer center xcancer omahaAmerican cancer instituteAccess programDrug administrationAmerican cancer societyProstate specific antigenResponse evaluation criteria in solid tumoursExpanded access programUrologic medical oncologistPrincipal investigator

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level
malaysiasun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from malaysiasun.com Daily Mail and Mail on Sunday newspapers.

New south walesUnited statesLuke nordquistAlan taylorPrnewswire clarity pharmaceuticalsAmerican cancer societyUrology cancer center xcancer omahaDrug administrationAccess programClarity pharmaceuticalsAmerican cancer instituteProstate specific antigenResponse evaluation criteria in solid tumoursExpanded access programUrologic medical oncologistPrincipal investigator

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level
singaporestar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from singaporestar.com Daily Mail and Mail on Sunday newspapers.

New south walesUnited statesLuke nordquistAlan taylorDrug administrationPrnewswire clarity pharmaceuticalsAmerican cancer societyUrology cancer center xcancer omahaClarity pharmaceuticalsAccess programAmerican cancer instituteProstate specific antigenResponse evaluation criteria in solid tumoursExpanded access programUrologic medical oncologistPrincipal investigator

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level
vietnamtribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vietnamtribune.com Daily Mail and Mail on Sunday newspapers.

New south walesUnited statesAlan taylorLuke nordquistPrnewswire clarity pharmaceuticalsAccess programAmerican cancer instituteDrug administrationClarity pharmaceuticalsUrology cancer center xcancer omahaAmerican cancer societyProstate specific antigenResponse evaluation criteria in solid tumoursExpanded access programUrologic medical oncologistPrincipal investigator